Alpha-1-antitrypsin expression in the lung is increased by airway delivery of gene-transfected macrophages

Gene Therapy

Volumn 10, Issue 26, 2003, Pages 2148-2152

  Zhang, D ^a   Wu, M ^a,b   Nelson, D E ^a,b   Pasula, R ^a   Martin II, W J ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BAL; hA1AT; rAAV; Ventilation

Indexed keywords

ALPHA 1 ANTITRYPSIN; MESSENGER RNA; PARVOVIRUS VECTOR; PLASMID DNA; RECOMBINANT PROTEIN; VIRUS VECTOR;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CULTURE MEDIUM; DNA PACKAGING; DRUG DETERMINATION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; GENE THERAPY; GENETIC CODE; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG EMPHYSEMA; LUNG LAVAGE; MACROPHAGE; MOUSE; MOUSE STRAIN; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEINASE INHIBITION; RECOMBINANT PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; VIRUS RECOMBINANT;

ADMINISTRATION, INHALATION; ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; DEPENDOVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE THERAPY; GENETIC VECTORS; LUNG; MACROPHAGES, ALVEOLAR; MICE; MICE, INBRED C57BL; PULMONARY EMPHYSEMA; TRANSFECTION;

ADENO-ASSOCIATED VIRUS; ANIMALIA; MURINAE; PARVOVIRUS;

EID: 0347407815     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302121     Document Type: Article

References (37)

1. Carrell RW, Lomas DA. Alpha1-antitrypsin deficiency - a model for conformational diseases. N Engl J Med 2002; 346: 45-53.
2. Coakley RJ, Taggart C, O'Neill S, McElvaney NG. Alpha1-antitrypsin deficiency: biological answers to clinical questions. Am J Med Sci 2001; 321: 33-41.
3. Wencker M, Fuhrmann B, Banik N, Konietzko N. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest 2001; 119: 737-744.
4. Mullins CD, Huang X, Merchant S, Stoller JK. The direct medical costs of alpha (1)-antitrypsin deficiency. Chest 2001; 119: 745-752.
5. Dasi F et al. Asialofetuin liposome-mediated human alpha1-antitrypsin gene transfer in vivo results in stationary long-term gene expression. J Mol Med 2001; 79: 205-212.
6. Rosenfeld MA et al. Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. Science 1991; 252: 431-434.
7. Kay MA, Graham F, Leland F, Woo SL. Therapeutic serum concentrations of human alpha-1-antitrypsin after adenoviral-mediated gene transfer into mouse hepatocytes. Hepatology 1995; 21: 815-819.
8. Kay MA et al. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat Genet 1995; 11: 191-197.
9. Setoguchi Y, Jaffe HA, Chu CS, Crystal RG. Intraperitoneal in vivo gene therapy to deliver alpha 1-antitrypsin to the systemic circulation. Am J Respir Cell Mol Biol 1994; 10: 369-377.
10. Levy MY, Barron LG, Meyer KB, Szoka Jr FC. Characterization of plasmid DNA transfer into mouse skeletal muscle: evaluation of uptake mechanism, expression and secretion of gene products into blood. Gene Therapy 1996; 3: 201-211.
11. Schiedner G et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998; 18: 180-183.
12. Morral N et al. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha 1-antitrypsin with negligible toxicity. Hum Gene Ther 1998; 9: 2709-2716.
13. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996; 70: 8098-8108.
14. Flotte TR et al. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci USA 1993; 90: 10613-10617.
15. Jooss K, Yang Y, Fisher KJ, Wilson JM. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998; 72: 4212-4223.
16. Flotte TR, Laube BL. Gene therapy in cystic fibrosis. Chest 2001; 120: 124S-131S.
17. Song S et al. Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors. Gene Therapy 2001; 8: 1299-1306.
18. Song S et al. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci USA 1998; 95: 14384-14388.
19. Stecenko AA, Brigham KL. Gene therapy progress and prospects: alpha-1 antitrypsin. Gene Therapy 2003; 10: 95-99.
20. Gill DR et al. Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor 1alpha promoter. Gene Therapy 2001; 8: 1539-1546.
21. Wu M et al. Genetically engineered macrophages expressing IFN-gamma restore alveolar immune function in scid mice. Proc Natl Acad Sci USA 2001; 98: 14589-14594.
22. Xiao W et al. Adeno-associated virus as a vector for liver-directed gene therapy. J Virol 1998; 72: 10222-10226.
23. Collaco RF, Cao X, Trempe JP. A helper virus-free packaging system for recombinant adeno-associated virus vectors. Gene 1999; 238: 397-405.
24. Gardi C et al. Neutrophil lysosomal dysfunctions in mutant C57 B1/6J mice: interstrain variations in content of lysosomal elastase, cathepsin G and their inhibitors. Biochem J 1994; 299 (Part 1): 237-245.
25. Rennard ST et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 1986; 60: 532-538.
26. Wewers MD et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987; 316: 1055-1062.
27. Gadek JE et al. Danazol-induced augmentation of serum alpha-1-antitrypsin levels in individuals with marked deficiency of this antiprotease. J Clin Invest 1980; 66: 82-87.
28. Wewers MD et al. Evaluation of danazol therapy for patients with PiZZ alpha-1-antitrypsin deficiency. Am Rev Respir Dis 1986; 134: 476-480.
29. Schwaiblmair M, Vogelmeier C, Fruhmann G. Long-term augmentation therapy in twenty patients with severe alpha-1-antitrypsin deficiency - three-year follow-up. Respiration 1997; 64: 10-15.
30. Yuan ZA, Soprano KJ, Kueppers F. Alpha-1 antitrypsin response of stimulated alveolar macrophages. J Cell Biochem 1992; 49: 410-416.
31. Hu C, Perlmutter DH. Cell-specific involvement of HNF-1beta in alpha(1)-antitrypsin gene expression in human respiratory epithelial cells. Am J Physiol Lung Cell Mol Physiol 2002; 282: L757-765.
32. Cichy J, Potempa J, Travis J. Biosynthesis of alpha1-proteinase inhibitor by human lung-derived epithelial cells. J Biol Chem 1997; 272: 8250-8255.
33. Crystal RG. Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. J Clin Invest 1990; 85: 1343-1352.
34. Vogelmeier C et al. The intrapulmonary half-life and safety of aerosolized alpha1-protease inhibitor in normal volunteers. Am J Respir Crit Care Med 1997; 155: 536-541.
35. 123 alpha1-protease inhibitor: toward a new therapeutic concept of alpha1-protease inhibitor deficiency? J Nucl Med 2001; 42: 744-751.
36. Dhami R et al. Pulmonary epithelial expression of human alpha1-antitrypsin in transgenic mice results in delivery of alpha1-antitrypsin protein to the interstitium. J Mol Med 1999; 77: 377-385.
37. Pasula R, Weaver T, Martinez MA, Martin II WJ. Morphologic detection and functional assessment of reconstituted normal alveolar macrophages in the lungs of SCID mice. J Immunol 2002; 169: 4504-4510.